drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-T)
drug_description
Autologous, gene-modified CD19-directed CAR T-cell therapy (also known as CNCT19) in which a patient’s T cells are engineered to express a CAR targeting CD19, leading to T-cell activation, cytotoxic killing of CD19+ B-cell malignancies, and B-cell aplasia.
nci_thesaurus_concept_id
C199061
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically modified to express a CD19-directed chimeric antigen receptor; upon binding CD19 on B-cell malignancies, CAR signaling (CD3zeta with costimulation) activates T-cell cytotoxicity and cytokine release, resulting in perforin/granzyme-mediated killing of CD19+ cells and on-target B-cell aplasia.
drug_name
Inaticabtagene autoleucel
nct_id_drug_ref
NCT06461351